L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

Clinical trial NCT04203641 · TERMINATED

Trial details

NCT number: NCT04203641
Sponsor: Helix BioPharma Corporation
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Pancreas Cancer

Start date: 2019-12-11
Primary completion: 2024-10-24
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.